GABA-A PAM Anxiolytic
Anxiety Disorders (General, Panic, Social) & Withdrawal-Induced Anxiety (Opioid/Alcohol Use Disorder)
PreclinicalActive
Key Facts
Indication
Anxiety Disorders (General, Panic, Social) & Withdrawal-Induced Anxiety (Opioid/Alcohol Use Disorder)
Phase
Preclinical
Status
Active
Company
About Zena Therapeutics
Zena Therapeutics is a private, preclinical biotech company founded in 2018 and based in Cambridge, USA. The company is developing a novel platform of GABA-A receptor PAMs with a ceiling effect on respiratory depression, aiming to create fast-acting anxiolytics with reduced abuse liability and fatal overdose risk. Its initial focus is on anxiety disorders and withdrawal-induced anxiety from opioid and alcohol use disorder. The company has secured over $1.7MM in non-dilutive grants and pre-seed funding to advance its lead candidate.
View full company profile